Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BIO105
- Development stage
- Preclinical
- Lead developer
- Boostimmune
- Modality
- Immunomodulatory ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
BIO105 (also known as BIO-105) is an early-stage immune-stimulating antibody conjugate (ISAC) being developed by Boostimmune. It is designed to target and modulate immunosuppressive myeloid cells, specifically myeloid-derived suppressor cells (MDSCs), within the tumor microenvironment to activate anti-tumor immune responses. BIO105 is currently in the discovery/preclinical stage of development for the treatment of neoplasms (cancer).
Beyond the preview
Go deeper on BIO105.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BIO105.